Published June 2, 2026 · Updated June 2, 2026 · 15 min read · Evidence-Based
The global anti-aging supplement market is projected to reach $10.65 billion by 2035, growing at 7.88% annually. Two compounds dominate the conversation among serious longevity practitioners: cycloastragenol (CAG) and NMN (nicotinamide mononucleotide). Both promise cellular rejuvenation, but they operate through entirely different biological pathways.
Before comparing specific compounds, understand the landscape. The anti-aging supplement market was valued at $5.28 billion in 2026 and is accelerating. Key drivers include:
Within this market, collagen dominates at 30.73% market share by ingredient, followed by vitamins and NAD+ boosters. But cycloastragenol occupies a unique niche: it is the only natural compound with human RCT data specifically for telomerase activation.
NMN is an NAD+ precursor. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, essential for:
NAD+ levels decline approximately 50% by age 50. NMN restores them. The NAD+ precursor market reached $346 million in 2025 and is projected at $557 million by 2027.
Cycloastragenol (CAG) is a triterpenoid saponin from Astragalus membranaceus. It is the only natural compound reported to activate telomerase — the enzyme that rebuilds telomere caps at chromosome ends. Telomeres shorten with each cell division; when critically short, cells enter senescence or apoptosis.
Human studies suggest:
| Factor | Cycloastragenol (CAG) | NMN |
|---|---|---|
| Primary Target | Telomerase activity / telomere maintenance | NAD+ repletion / mitochondrial support |
| Mechanism | Upregulates hTERT gene expression | NAD+ salvage pathway precursor |
| Human RCT Data | Yes - telomere markers studied | Limited - mostly preclinical/animal |
| Bioavailability Challenge | 91.8% hepatic first-pass loss documented | Moderate - gut degradation issues |
| Delivery Solution | Liposomal + cyclodextrin + bioactivation | Liposomal or sublingual forms |
| Cost (30-day supply) | $54.99 - $79.99 | $40 - $120 |
| Optimal Pairing | With NMN for dual-pathway coverage | With CAG for telomere support |
Here is the critical issue with standard cycloastragenol: published research documents that 91.8% is destroyed by hepatic first-pass metabolism before reaching systemic circulation. A 10mg standard capsule may deliver less than 1mg to your cells. This explains why many users of generic CAG supplements report minimal effects.
TELOGENIS addresses this with a three-layer delivery architecture:
Without this architecture, you are paying for CAG that never leaves your liver.
| Your Goal | Recommended Protocol |
|---|---|
| Maximize healthspan / biological age optimization | Stack both: CAG 17mg + NMN 500mg daily |
| Telomere maintenance specifically | CAG foundation - the only researched natural telomerase compound |
| Energy / mitochondrial support | NMN priority - superior for ATP production |
| Budget-conscious entry | CAG 10mg - lower cost, unique mechanism |
| Advanced biohacker protocol | CAG 20mg + NMN + fisetin + omega-3 |
NMN and cycloastragenol are not competitors. They are complementary tools targeting different hallmarks of aging. NMN addresses mitochondrial dysfunction. CAG addresses telomere attrition. The most sophisticated longevity protocols use both.
If you can only choose one, the decision depends on your biomarker status and goals:
Harley CB, et al. (2011). A natural product telomerase activator as part of a health maintenance program. Rejuvenation Research. PMID: 20822369
Zhu J, et al. (2010). The effects of cycloastragenol on the absorption and bioavailability of drugs. Pharmaceutical Research.
Imai S, Guarente L (2014). NAD+ and sirtuins in aging and disease. Trends in Cell Biology. PMID: 24786309
Mills KF, et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism. PMID: 28068222
Anti-aging Supplements Market Report (2026). SNS Insider. Market valued at $5.00B in 2025, projected $10.65B by 2035.